All Articles
Listen to perspectives on CS diarrhea from Dr. David C. Metz, gastroenterologist and neuroendocrine tumor expert. Read More ›
The American Society of Clinical Oncology (ASCO) has developed a proposal for an Alternative Payment Model that is focused on delivering value in oncology and supporting higher-quality and more affordable cancer care. Read More ›
By Wayne Kuznar
The ideal treatment in 2017 for patients with newly diagnosed multiple myeloma is a combination of bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone. Bortezomib-based maintenance therapy is particularly relevant in patients with high-risk disease and residual disease, and in the relapsed setting, triplet therapy is preferred over doublet therapy. Read More ›
“Are we really measuring quality, or are we measuring our ability to report?” asked Brian R. Bourbeau, MBA, Director, Practice Operations, Oncology Hematology Care, the US Oncology Network, Cincinnati, OH. “So far it’s been the latter,” he said. Read More ›